Search

Search


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Search results for {{term}}

66. Boost for liver disease trial

Boost for liver disease trial Date: 24/11/2014Researchers from the University of Edinburgh have received funding to start testing the therapy in patients within the next year.It will be the world’s first clinical trial of a new type of cell therapy to treat liver cirrhosis, a common disease where scar tissue forms in the organ as a result of long-term damage.The Edinburgh team has received funding from the Medical Research Council and Innovate UK to investigate the disease, which clai


67. Publication of Circular and Notice of General Meeting relating to the

Publication of Circular and Notice of General Meeting relating to the proposed major transaction with Novartis Date: 25/11/2014GlaxoSmithKline plc (the “Company”, “GSK”) announced a major three-part inter-conditional transaction with Novartis AG involving its Consumer Healthcare, Vaccines and Oncology businesses (the “Transaction”).The proposed Transaction would substantially strengthen two of our core businesses in vaccines and consumer healthcare and cr


68. Incruse® Ellipta® (umeclidinium) to be reimbursed in Australia for Chronic Obstructive Pulmonary Disease

 Incruse® Ellipta® (umeclidinium) to be reimbursed in Australia for Chronic Obstructive Pulmonary Disease Date:01/12/2014 Reimbursed via the Pharmaceutical Benefits Scheme from 1st December 2014 - Administered using a new dry powder inhaler called Ellipta1GlaxoSmithKline (GSK) has welcomed the listing of Incruse Ellipta (umeclidinium) on the Australian Pharmaceutical Benefits Scheme (PBS) from December 1st 2014 as a long term once-daily, maintenance bronchodilator t


69. Manchester University announces new graphene partners

Manchester University announces new graphene partners Date:09/12/2014Two more companies have finalised collaborative partnerships with The University of Manchester to work on graphene applications of the future.Morgan Advanced Materials and 2D-Tech have both agreed long-term research collaborations with the National Graphene Institute (NGI), the £61m centre at the University set to open in early 2015.The news coincided with the first industry tour of the NGI this week, w


70. GSK drops plan to sell older drugs

GSK drops plan to sell older drugs Date:09/12/2014GlaxoSmithKline said that it had decided not to sell a portfolio of older drugs marketed in North America and Europe after considering offers from potential buyers."The company has evaluated all bids received and has concluded, consistent with its key criteria of maximising shareholder value, not to pursue divestment of these products," it said in a statement.A spokesman for GSK, which was being advised on the disposal by Lazard, declined to



Page 14 of 44 ( 219 results in total )
© Catalyst Innovation Portal 2019